Ajanta Pharma Ltd

Ajanta Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ajanta Pharma Ltd

₹ 3,035 -1.41%
08 May - close price
ajantapharma.com BSE: 532331 NSE: AJANTPHARM
About

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Key Points

India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]

Website BSE NSE
  • Market Cap ₹ 37,918 Cr.
  • Current Price ₹ 3,035
  • High / Low ₹ 3,228 / 2,330
  • Stock P/E 35.9
  • Book Value ₹ 362
  • Dividend Yield 0.92 %
  • ROCE 32.3 %
  • ROE 25.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 8.38 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty500 Shariah

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
882 1,021 1,028 1,105 1,054 1,145 1,187 1,146 1,170 1,303 1,354 1,375 1,422
732 750 738 791 776 815 875 825 873 951 1,026 993 1,088
Operating Profit 149 271 291 314 278 330 311 321 297 351 328 382 333
OPM % 17% 27% 28% 28% 26% 29% 26% 28% 25% 27% 24% 28% 23%
37 32 21 14 36 26 19 30 18 26 59 25 61
Interest 1 1 2 2 2 1 6 8 6 5 3 5 2
Depreciation 33 33 34 34 34 34 34 36 40 41 43 44 45
Profit before tax 152 269 276 291 278 322 290 307 269 331 341 359 347
Tax % 20% 23% 29% 28% 27% 24% 25% 24% 16% 23% 24% 24% 23%
122 208 195 210 203 246 216 233 225 255 260 274 267
EPS in Rs 9.54 16.24 15.24 16.39 15.82 19.68 17.33 18.64 18.03 20.44 20.83 21.91 21.35
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,474 1,749 1,983 2,126 2,055 2,588 2,890 3,341 3,743 4,209 4,648 5,453
968 1,155 1,292 1,467 1,489 1,904 1,889 2,408 2,934 3,037 3,379 4,058
Operating Profit 505 594 691 658 567 683 1,001 933 808 1,172 1,269 1,395
OPM % 34% 34% 35% 31% 28% 26% 35% 28% 22% 28% 27% 26%
8 14 20 24 21 88 24 112 74 85 85 172
Interest 6 5 1 0 1 12 8 10 6 7 21 16
Depreciation 52 44 61 60 72 96 116 125 131 135 144 173
Profit before tax 456 559 648 623 514 664 900 909 745 1,114 1,189 1,378
Tax % 32% 26% 22% 25% 25% 30% 27% 22% 21% 27% 23% 23%
310 416 507 469 387 468 654 713 588 816 920 1,056
EPS in Rs 23.47 31.49 38.40 35.50 29.56 35.73 50.38 55.63 45.89 63.70 73.68 84.52
Dividend Payout % 17% 17% 23% 0% 20% 24% 13% 11% 15% 79% 38% 0%
Compounded Sales Growth
10 Years: 12%
5 Years: 14%
3 Years: 13%
TTM: 17%
Compounded Profit Growth
10 Years: 10%
5 Years: 10%
3 Years: 21%
TTM: 15%
Stock Price CAGR
10 Years: 12%
5 Years: 19%
3 Years: 34%
1 Year: 20%
Return on Equity
10 Years: 23%
5 Years: 23%
3 Years: 25%
Last Year: 25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 18 18 18 18 18 18 17 17 25 25 25 25
Reserves 823 1,173 1,550 2,024 2,228 2,581 2,978 3,247 3,363 3,542 3,765 4,502
72 81 1 2 36 75 31 25 36 35 47 260
233 207 254 383 383 619 702 711 1,159 927 1,067 1,368
Total Liabilities 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904 6,155
288 451 589 1,053 1,178 1,472 1,541 1,512 1,496 1,479 1,762 1,867
CWIP 170 240 339 61 262 132 108 153 209 256 176 258
Investments 60 86 182 190 78 79 176 147 535 349 464 588
629 703 713 1,122 1,147 1,610 1,904 2,188 2,341 2,446 2,502 3,441
Total Assets 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904 6,155

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
279 326 609 281 375 457 576 562 792 785 1,157 529
-158 -209 -383 -256 -223 -224 -282 -74 -560 65 -377 -429
-105 -117 -202 -0 -147 -129 -318 -460 -108 -1,051 -733 -168
Net Cash Flow 16 -0 24 25 4 104 -24 28 124 -201 47 -68
Free Cash Flow 176 29 313 19 32 228 417 431 618 646 840 169
CFO/OP 84% 82% 110% 64% 87% 89% 81% 86% 117% 94% 117% 64%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 64 78 59 79 82 109 93 111 103 108 93 124
Inventory Days 159 180 186 315 415 276 434 347 283 283 308 289
Days Payable 109 128 157 224 214 202 212 143 147 159 155 168
Cash Conversion Cycle 114 130 88 170 282 184 315 315 240 233 246 246
Working Capital Days 56 78 65 103 113 108 126 140 83 119 97 148
ROCE % 57% 52% 46% 34% 24% 27% 32% 29% 23% 32% 32% 32%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Annual New Product Launches (India)
Number ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Commercialized ANDAs in US
Number
Number of Manufacturing Plants
Number
Pending ANDA Approvals with USFDA
Number
India Medical Representatives (MRs)
Number ・Standalone data
India Branded Generic Products Portfolio
Number ・Standalone data
Number of R&D Scientists
Number
Total Medical Representatives (MRs)
Number
Active ANDA Status (US)
Number
R&D Scientists
Number
Total ANDAs Commercialized (US)
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
66.22% 66.22% 66.22% 66.22% 66.27% 66.26% 66.26% 66.26% 66.26% 66.25% 66.25% 66.25%
10.19% 9.99% 9.11% 8.54% 8.36% 9.11% 9.26% 8.86% 8.86% 8.53% 7.97% 8.26%
15.36% 15.60% 16.67% 17.48% 17.41% 17.09% 17.02% 17.48% 17.50% 17.90% 18.58% 18.36%
0.46% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
7.78% 8.21% 8.00% 7.76% 7.94% 7.51% 7.45% 7.38% 7.38% 7.32% 7.20% 7.14%
No. of Shareholders 54,87456,27754,35155,48870,31664,31566,89670,82768,88267,78565,40967,955

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls